1. PRACTICE PATTERNS OF RADIOTHERAPY IN CERVIX CANCER AMONG MEMBER GROUPS OF THE GYNECOLOGIC CANCER INTERGROUP (GCIG) D GAFFNEY 1, A DU BOIS 2, K NARAYAN 3, N REED 4, T TOITA 5, S PIGNATA 6, P BLAKE 7, L PORTELANCE 8, A SADOYZE 9, R POTTER 10, A COLOMBO 11, M RANDALL 12, MR MIRZA 13, EL TRIMBLE 14, 1 RTOG, USA 2 AGO-OVAR, Germany 3 ANZGOG, Australia/New Zealand 4 EORTC, Scotland 5 JGOG, Japan 6 MITO, Italy 7 Royal Marsden Hospital, England 8 NCIC, Canada 9 SGCTG, Scotland 10 AGO-AUST, Austria 11 MANGO, Italy 12 GOG, USA 13 NSGO, Scandinavia 14 NCI, USA

2. RTOG USA JGOG Japan MITO Italy EORTC ANZGOG Australia/New Zealand AGO-OVAR Germany MRC (NRCI) NCIC CanadaAGO-AUST Austria SGCTG Scotland MANGO Italy NSGO Scandinavia GEICO Spain GINECO France GOG USA

3. Methods Survey Developed Radiotherapy practice –Indications –Doses –Fields –Chemotherapy –Brachytherapy 4 questionnaires per group 39 returned from 13 groups Descriptive statistics

4. RT Doses Gy 47.9 +/- 2.9 48.0 +/- 3.5 79.1 +/- 7.9 57.9 +/- 5.5 45.6 +/- 2.7 46.9 +/- 5.1

5. Total Point A Doses: North America Compared to Other Cooperative Groups Gy 81.8 77.4 p=0.103

6. Type of Simulation for Definitive RT 33 1 1

7. Size of Pelvic Field for Definitive RT 17 4 5 8 N=34

8. IMRT in Definitive RT? N=27

9. Type of Chemotherapy for Definitive RT? 30 2 4 1 N=37

10. Dosing of CDDP for Definitive RT (n=30)

11. Adjuvant Chemo post Hysterectomy and Concurrent ChemoRT N=34

12. Intervene for a low Hemoglobin 31 N=33

13. Type of Brachytherapy for Definitive RT 25 N=29

14. Indications for Para-aortic RT

15. Upper Border for Para-aortic RT N=31

16. Vaginal Brachytherapy post Hysterectomy 18 Rx’d to ½ cm, 8 to Vag surface, 1 to one cm 23/25 recorded dose to bladder and rectum 23/27 used HDR For HDR –Median dose: 17.5 Gy –Median dpf: 6 Gy Degree of Vagina Treated

17. Conclusions Radiotherapy Practices among members of GCIG are similar in terms of doses and fields Concomitant chemotherapy is used by all groups with CDDP predominating There is no consensus on vaginal brachytherapy prescription Radiotherapy practices should not be a barrier to intergroup participation in clinical trials

18. Acknowledgments Mason Schoenfeldt and Monica Bacon Executive Board of the GCIG Respondents Collegiality among all members